Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 7:30 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 7:30 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks.com featured highlights include Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp
by Zacks Equity Research
Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength in a Volatile Market
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are KNSA, HNI, AEYE, BCPC, GRC.
Best Momentum Stocks to Buy for August 1st
by Zacks Equity Research
CVNA, QCRH, and KNSA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 1, 2024.
New Strong Buy Stocks for August 1st
by Zacks Equity Research
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know
by Zacks Equity Research
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 33.33% and 23.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
by Zacks Equity Research
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
by Zacks Equity Research
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for February 29th
by Zacks Equity Research
UGP, KNSA, EIG, AMSF and HMC have been added to the Zacks Rank #1 (Strong Buy) List on February 29, 2023.
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 136.36% and 15.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
GSK (GSK) Misses Q4 Earnings Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of -5.26% and 2.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.9% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Is Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.
Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 70.3% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -11.11% and 7.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?